CClinicalTrials.gg
CompletedNCT05466279Updated Jan 25, 2024

The Role of Remazolam in Reducing the Incidence of Postoperative Delirium in Elderly Patients

An interventional study of remazolam and Propofol in Postoperative Delirium, sponsored by Fang Jun. Completed at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Fang Jun · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2021, registered Jul 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This study is a prospective, randomized, controlled trial.The selected patients were randomly divided into remazolam general anesthesia group and propofol + midazolam general anesthesia control group according to computer randomization method. There were 65 patients in each group. Remazolam general anesthesia group (R group): Remazolam 0.4 mg/kg for rapid induction of loss of consciousness for anesthesia induction and 1 mg/kg/h for maintenance. Propofol + midazolam general anesthesia control group (group P): propofol 1.5 mg/kg + midazolam 0.05 mg/kg slow intravenous push until the patient's consciousness disappeared, then propofol 4-8 mg/kg/h Anesthesia was maintained. Except for different sedative drugs, the analgesic and muscle relaxant medication regimens were the same between the two groups. In the study, the application of inhaled anesthetics, other benzodiazepines and anticholinergic drugs was restricted, and the mean arterial pressure during the operation was kept above 60 mmHg to avoid perioperative hypotension, hypoxemia, and hypercapnia. Warm measures were used to maintain the patient's intraoperative body temperature above 36.0 °C. POD assessment was performed on the day before surgery and on days 1-7 after surgery.

02

Conditions studied

  • Postoperative Delirium
03

In context

Delirium

1,057 studies on the registry are indexed under Delirium; 238 are open to participants now.

This study's enrollment of 131 is close to the median of 120 across 599 interventional studies indexed under Delirium.

Browse Delirium studies →

Lead sponsor

This is the only study on the registry with Fang Jun as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Elderly patients with limited abdominal tumor surgery (age ≥65 years)
  • ASA classification I-III.

Exclusion criteria

Exclusion Criteria:

  • Refusing to participate in the study
  • Patients with severe arrhythmia or cardiac dysfunction (EF\<35%)
  • A clear history of neurological and psychiatric disorders before surgery or long-term use of sedatives or antidepressants
  • History of alcoholism or drug dependence
  • History of brain surgery or trauma
  • Severe vision or hearing impairment
  • Inability to cooperate with the completion of cognitive function tests
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Remazolam general anesthesia group (R group)

    Drug: remazolam

  • Active comparator
    Propofol + midazolam general anesthesia control group (group P)

    Drug: Propofol · Drug: Midazolam

Interventions

  • Drugremazolam

    Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.

  • DrugPropofol

    Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus

  • DrugMidazolam

    Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium

    Proportion of patients with postoperative delirium among enrolled patients. The incidence of delirium during recovery was assessed by the Confusion Assessment Method-ICU (CAM-ICU). The assessment time points were: 10 minutes, 30 minutes after entering the anesthesia recovery room (or exiting the recovery room). The incidence of delirium within 7 days after surgery was assessed using 3D-CAM to assess whether patients had delirium.

    Time frame: Postoperative, 7 days

Secondary outcomes

  1. Intraoperative awareness rate

    The modified Brice interview over quality assurance techniques in detecting intraoperative awareness with explicit recall.

    Time frame: Postoperative, 24 hours

  2. Intraoperative hemodynamic stability

    The change curve of intraoperative mean arterial blood pressure and heart rate

    Time frame: Intraoperative, 6 hours

  3. Richard-campbell Sleep Questionnaire Score

    Richards-Campbell Sleep Questionnaire (RCSQ) is a five-item、 visual analogue scale was designed for assessing sleep quality of patients

    Time frame: Postoperative, 3 days

  4. Perioperative nutritional status score table(PONS)

    Perioperative Nutrition Screen (PONS). This algorithmic approach is used to identify perioperative malnutrition risk and guide perioperative nutrition intervention. BMI, body mass index

    Time frame: Baseline, 1 year

  5. Modified frailty rating scale

    Modified Frailty Index Frailty index is an important predictive variable in emergency general surgery patients older than 60 years. The modified frailty index can be used to evaluate risk of both morbidity and mortality in these patients.

    Time frame: Baseline, 1 year

  6. Postoperative hospital stay

    Taking the operation day as the starting point, calculating the length of stay in the hospital after the operation

    Time frame: Postoperative, 3 months

  7. Postoperative nausea and vomiting

    The proportion of patients with nausea and vomiting within 7 days after surgery

    Time frame: Postoperative, 7 days

07

Study locations

1 site
  • Zhejiang Cancer Hospital
    Hanzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05466279
Lead sponsor
Fang Jun
Responsible party
Fang Jun (Clinical Professor, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Jul 20, 2022
Start date
Jan 7, 2021
Primary completion
Oct 30, 2023
Completion
Oct 30, 2023
Last update
Jan 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion